Advertisement
Eli Lilly
Subscribe to Eli Lilly

The Lead

Eli Lilly, Sanford-Burnham Announce Collaboration

May 14, 2015 12:00 pm | by Eli Lilly and Company | News | Comments

Eli Lilly and Company and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies.

Eli Lilly to Build Drug Delivery Innovation Center

May 6, 2015 11:20 am | by Eli Lilly | News | Comments

Eli Lilly and Company today announced plans to establish a new drug delivery and device...

Eli Lilly Biomanufacturing Plant For Sale

April 21, 2015 10:54 am | News | Comments

CBRE Group, Inc. announced today that they have been hired to sell Eli Lilly’s biomanufacturing...

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

March 23, 2015 8:07 am | News | Comments

Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical...

View Sample

FREE Email Newsletter

FDA Approves Glyxambi Tablets for Adults with Type 2 Diabetes

February 2, 2015 10:59 am | News | Comments

The FDA has approved Glyxambi (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments.

Lilly Beats Wall Street Fourth Quarter Forecasts

January 30, 2015 8:34 am | News | Comments

Eli Lilly has reported fourth-quarter net income of $428.5M. On a per-share basis, the Indianapolis-based company said it had profit of 40 cents. Earnings, adjusted for asset impairment costs and costs related to mergers and acquisitions, came to 75 cents per share.

Lilly, Merck to Collaborate on Immuno-Oncology Combination Regimens in Multiple Types of Cancer

January 13, 2015 8:17 am | News | Comments

Merck and Eli Lilly announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials.

Advertisement

Lilly Provides Update on Strategy and Announces 2015 Financial Guidance

January 7, 2015 8:04 am | News | Comments

Eli Lilly and Company today announced its 2015 financial guidance and outlined plans to grow revenue and expand margins through the balance of the decade. The company's refined strategy will provide greater focus for research and commercial activities and help maintain a sustainable flow of innovative medicines.

Lilly Closes Novartis Deal to Create Huge Animal Health Business

January 2, 2015 8:17 am | News | Comments

Just over a week after saying it would sell its heartworm treatment for dogs at the request of federal regulators, Eli Lilly announced that it has completed its $5.4 billion acquisition of the animal health division belonging to Switzerland's Norvartis.

Eli Lilly to Sell Heartworm Line for Novartis Deal Approval

December 22, 2014 2:20 pm | News | Comments

The Federal Trade Commission is requiring the sale of Eli Lilly's Sentinel heartworm products because the Novartis deal would reduce competition and lead to higher prices. Eli Lilly will sell Sentinel to French pharmaceutical company Virbac.  

Eli Lilly Bumps Dividend for First Time Since 2009

December 16, 2014 10:54 am | News | Comments

Lilly has been dealing with a drop in both earnings and revenue due to the loss of patents protecting key drugs from cheaper generic competition. Company executives have said they remained committed to the dividend, despite the financial blows the company was absorbing, but some analysts have questioned whether that commitment might waver.

Lilly's Cyramza Gets New Marketing Approval

December 15, 2014 8:12 am | News | Comments

The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread. Earlier this year the FDA approved the drug as a treatment for gastric cancer.          

Advertisement

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.

Charges Dropped Against Two Former Lilly Scientists

December 8, 2014 8:34 am | News | Comments

Two former Eli Lilly and Co. employees who were accused of sending trade secrets worth more than $55 million to a competing Chinese drug company will no longer face charges, the U.S. attorney's office announced Friday.      

Lilly and Zosano Form $440M Osteoporosis Patch Deal

December 2, 2014 3:42 pm | News | Comments

Eli Lilly will invest $15 million in Zosano, which filed for an initial public offering earlier this year. Zosano, of Fremont, California, could get $300 million if its drug advances through regulatory review and another $125 million if it reaches sales targets.

Eli Lilly and AstraZeneca Start Pivotal Clinical Trial for Patients with Early Alzheimer's Disease

December 1, 2014 8:22 am | News | Comments

Eli Lilly and and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

Fifth Person Pleads Guilty in Eli Lilly Drug Warehouse Heist

November 25, 2014 10:09 pm | by The Associated Press | News | Comments

A fifth person has pleaded guilty to participating in a 2010 Connecticut warehouse heist that prosecutors say involved up to $100 million in prescription drugs. Cuban citizen and Miami resident Rafael Lopez pleaded guilty to a federal charge of deliberately hiding his knowledge of a felony.

Advertisement

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance

October 29, 2014 8:19 am | News | Comments

In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company are changing the operational and financial structure of their diabetes alliance in certain countries.

Patent Expirations Hit Eli Lilly Third Quarter Profit

October 23, 2014 1:43 pm | News | Comments

Eli Lilly said that its net income and sales sank in the third quarter after its antidepressant Cymbalta lost patent protection and faced competition from less-expensive generics. Lilly said its revenue from Cymbalta plunged 73%t and revenue from the osteoporosis treatment Evista fell 65%.

Eli Lilly Adds $375M to Zymeworks Partnership

October 22, 2014 5:37 pm | by The Associated Press | News | Comments

The companies announced a team-up in January but did not disclose terms. Without explaining the initial terms of the partnership, the companies said Zymeworks could get an additional $375M in milestones and other payments.     

FDA Accepts NDA for Empagliflozin/Metformin Fixed-Dose Combination

October 21, 2014 9:01 am | News | Comments

The FDA has accepted the filing of a New Drug Application for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes.  

Lilly to Realign Puerto Rico Manufacturing Operations

October 16, 2014 3:28 pm | News | Comments

Eli Lilly and Company has announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015. 

Novartis Says Three Members of Executive Committee to Leave Company

October 8, 2014 9:09 am | News | Comments

Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.

EU OKs Eli Lilly's $5.4B Bid for Novartis division

October 3, 2014 6:47 am | by The Associated Press | News | Comments

The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors.

Lilly Ends Lupus Drug Development Program

October 2, 2014 8:48 am | News | Comments

Eli Lilly and Company will discontinue development of tabalumab -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials.     

FDA Approves Eli Lilly's Injectable Diabetes Drug

September 18, 2014 4:46 pm | by The Associated Press | News | Comments

The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly and Co. for adults with the most common form of the disease. The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes.

AstraZeneca and Lilly to Develop and Commercialize Alzheimer’s Disease Treatment

September 16, 2014 8:39 am | News | Comments

AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.  

Lilly Says CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

September 12, 2014 8:56 am | News | Comments

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.   

Lilly Receives European Marketing OK for Insulin

September 10, 2014 10:58 am | News | Comments

European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent infringement litigation with French rival Sanofi.        

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading